In conclusion, we have shown that pharmacological inhibition of VAV3 by IODVA1 in preclinical models is therapeutically superior to inhibiting upstream kinases and thus an attractive therapeutic strategy to treat Ph+ and TKI-resistant Ph+ B-ALL. Here, VAV3 is linked to acute lymphoblastic leukemia.